tranylcypromine Side Effects
Also known as: Parnate
Analysis of 329 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
329
Death-Related
49
14.9% of reports
Hospitalizations
116
35.3% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 49 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| COMPLETED SUICIDE | 18 |
| DYSMORPHISM | 12 |
| ATRIOVENTRICULAR SEPTAL DEFECT | 11 |
| FOETAL EXPOSURE DURING PREGNANCY | 10 |
| DRUG INTERACTION | 9 |
| FOETAL DEATH | 8 |
| HYPERTHERMIA | 7 |
| SEROTONIN SYNDROME | 7 |
| TOXICITY TO VARIOUS AGENTS | 7 |
| HYPERTELORISM OF ORBIT | 6 |
| RESPIRATORY ARREST | 6 |
| RHABDOMYOLYSIS | 6 |
| ACIDOSIS | 5 |
| MYOCLONUS | 5 |
| PLACENTAL INFARCTION | 5 |
| CONTRAINDICATED PRODUCT ADMINISTERED | 4 |
| DEATH | 4 |
| DRUG DOSE TITRATION NOT PERFORMED | 4 |
| HAEMORRHAGE INTRACRANIAL | 4 |
| HYPOTENSION | 4 |
Reactions in Hospitalization Reports
Top reactions in 116 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DRUG INTERACTION | 20 |
| DEPRESSION | 18 |
| OFF LABEL USE | 15 |
| SEROTONIN SYNDROME | 14 |
| HYPERTENSION | 13 |
| HYPERTENSIVE CRISIS | 13 |
| BLOOD PRESSURE FLUCTUATION | 12 |
| CONTRAINDICATED PRODUCT ADMINISTERED | 11 |
| DRUG INEFFECTIVE | 11 |
| OVERDOSE | 11 |
| COMPLETED SUICIDE | 10 |
| HEADACHE | 10 |
| HYPERTHERMIA | 10 |
| PARAESTHESIA | 10 |
| POTENTIATING DRUG INTERACTION | 10 |
| SUICIDAL IDEATION | 10 |
| ABDOMINAL DISTENSION | 9 |
| MUSCULAR WEAKNESS | 9 |
| PRESCRIBED OVERDOSE | 9 |
| THERAPEUTIC RESPONSE UNEXPECTED | 9 |
Nearby — Related Medications
What the FAERS Data Reveals About tranylcypromine Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 329 voluntary reports linked to tranylcypromine and its brand equivalents (Parnate), spanning 2004 through 2025. Of those, 49 (14.9%) listed death as an outcome and 116 (35.3%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 63% were female and 35% male; age distribution skews toward 45-64, with 86 reports in that bracket. The single most reported reaction is drug interaction with 68 submissions, followed by depression and drug ineffective.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.